Clinical Trials | October 13, 2025
Moderna’s mRNA-4359 shows promising early results in resistant Melanoma at ESMO 2025
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
New results build on previously reported significant recurrence-free survival (rfs) benefit seen in these patients
This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program
The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
Subscribe To Our Newsletter & Stay Updated
